IP Cases — 2025
5,670 decisions across all jurisdictions
Page 108 of 189 · 5,670 total
Malikie Innovations Ltd. v.Discord Inc. and Discord Netherlands B.V.
This is a procedural order from the Mannheim Local Division concerning an infringement action regarding European patent EP 3 716 655. The defendants, Discord Inc. and Discord Netherlands B.V., belong to the same group of companies and requested harmonization of time periods for submitting their Statements of Defence and lodging any Counterclaim for Revocation, to which the claimant consented. The court granted the request, setting a uniform deadline of 2 July 2025 for both defendants.
Dolby International AB v.Roku, Inc.
This case concerns a review application by Roku, Inc. regarding an ex parte order granting Dolby International AB an Anti-Anti-Suit Injunction (AASI) and Anti-Anti-Enforcement Injunction (AAEI) before the Local Chamber Munich. The court declared the application for interim measures moot and the proceedings terminated, but held that Roku bore the costs because a prior cease-and-desist letter was unnecessary given Roku had already initiated US proceedings seeking Anti-Suit and Anti-Enforcement Injunctions against Dolby.
3VSigma v.AGA-ACEF
Order
Imperative Care, Inc. v.Inari Medical, Inc. et al.
In an IPR, the PTAB held that all nine claims of Inari Medical’s hemostasis valve patent are unpatentable under §§102 and 103, finding the petitioner’s anticipation and obviousness arguments persuasive.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB denied Imperative Care’s petition to review Inari Medical’s 11,744,691 patent covering catheter‑based embolism removal. The Board found the petitioner had not shown a reasonable likelihood of prevailing on any of the 31 challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care secured institution of an IPR against Inari Medical’s hemostasis‑valve patent, covering claims 1‑9, on grounds of anticipation and obviousness.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,697,011 hemostasis valve patent after Imperative Care demonstrated a reasonable likelihood of unpatentability on claims 1‑9.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,554,005 patent covering a vacuum aspiration system with hemostasis valve. Petitioner Imperative Care showed a reasonable likelihood of prevailing on at least one claim, especially claim 1, based on obviousness over Garrison, Schaffer and other references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care seeks an IPR of Inari Medical’s ’333 patent covering aspiration systems for pulmonary embolism and DVT, alleging obviousness over multiple prior‑art references. The petition requests the Board to institute review of 36 claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care successfully met the institution burden in its IPR against Inari Medical's '333 patent, establishing a reasonable likelihood of prevailing on key claims. The Board found that combining prior art references like Laub and Garrison renders the claimed thromboembolism treatment systems obvious under 103.
Dhunseri Petrochem And Tea Ltd. v.Mr. Dhanraj Khatri And Anr.
Dhunseri Petrochem And Tea Ltd. filed an application seeking rectification of a copyright registration held by its opponents, alleging that the respondent's artistic work was a deceptive and substantial reproduction of the petitioner's established labels ('Lal Ghora' and 'Kala Ghora'). The petitioner demonstrated long-standing use and exclusive association with their distinctive packaging designs for tea. The court found that the respondent's design was deceptively similar, noting only cosmetic changes while retaining the core features and color scheme. Consequently, the registration of the impugned artistic work was directed to be expunged.
Dura-Line India Pvt Ltd v.Jain Irrigation Systems Ltd.
Dura-Line India Pvt Ltd filed a suit against Jain Irrigation Systems Ltd., alleging infringement of its patent and design related to non-metallic pipes embedded with tracer cables for leak detection. The defendant challenged both the infringement and the validity of the patent itself. After extensive proceedings, the Delhi High Court ruled in favor of Dura-Line, upholding the validity of the Suit Patent and decreeing the suit.
Vikas Gupta / Neha Herbals Pvt. Ltd. v.Inder Raj Sahni Proprietor M/S Sahni Cosmetics
The Delhi High Court addressed a complex trademark dispute over the common name 'NEHA' used in the personal care sector. The Plaintiffs, Neha Herbals, claimed infringement and passing off against Sahni Cosmetics, which uses the mark for creams. While the court acknowledged the Defendant's prior use of the mark for creams, it ultimately found that the Plaintiffs had established continuous use and valid registrations for their goods (Mehandi). Consequently, the suit seeking damages was dismissed, but the cancellation petitions filed by the Defendant were also rejected.
OnePlus Technology (Shenzhen) Co., Ltd. et al. v.Pantech Corporation
OnePlus’s request to overturn a patent challenge on LTE/5G technology was denied. Pantech successfully defended the Director’s discretionary denial, emphasizing lack of examiner error and settled industry expectations.
OnePlus Technology (Shenzhen) Co., Ltd. et al. v.Pantech Corporation
OnePlus Technology seeks Director Review of the PTAB’s denial to institute an IPR on its 4G/5G uplink synchronization patent. The petition argues the “settled expectations” rule was misapplied and that material examiner error and the breadth of related patents merit Board review.
OnePlus Technology (Shenzhen) Co., Ltd. et al. v.Pantech Corporation
The USPTO denied OnePlus’s request for Director Review of the institution denial in IPR2025-00720 and related cases, leaving the original denial in place.
OnePlus Technology (Shenzhen) Co., Ltd. et al. v.Pantech Corporation
OnePlus has filed a petition for inter partes review of Pantech’s U.S. Patent 10,764,803 covering enhanced uplink operation in soft handover. The challenger asserts lack of written description and obviousness over several 3GPP standards and Ericsson documents, seeking cancellation of eight claims.
OnePlus Technology (Shenzhen) Co., Ltd. et al. v.Pantech Corporation
OnePlus has filed an IPR petition seeking to invalidate claims 1, 3 and 4 of Pantech’s ’776 patent covering uplink synchronization in multi‑component carrier LTE systems, citing Dinan and several 3GPP documents as prior art.
OnePlus Technology (Shenzhen) Co., Ltd. et al. v.Pantech Corporation
The PTAB issued an institution decision in the OnePlus vs. Pantech IPR, finding reasonable likelihood that certain claims are unpatentable under 35 U.S.C. § 103. The Board's analysis hinged on detailed claim construction and the obviousness arguments presented against various 3GPP specifications and industry standards like Ericsson.
DDP Specialty Electronic Materials US, LLC. v.Greenchemicals S.R.L.
This is a preliminary procedural order issued by the Düsseldorf Local Division concerning EP 1 957 544 B1, addressing the Applicant's request to classify certain financial information as confidential under R. 262A RoP. The court granted the confidentiality order, classifying specific financial information in the Applicant's comments and Exhibit HL 15 as confidential, while rejecting the Defendant's arguments that the information was publicly available. Access was limited to the Defendant's representatives and one named administrative employee, with penalties for culpable breach.
Generac Power Systems, Inc. et al. v.Champion Power Equipment, Inc.
Generac, Harbor Freight and MWE have settled their IPR against Champion’s dual‑fuel selector switch patent and request the Board keep the settlement confidential.
Generac Power Systems, Inc. et al. v.Champion Power Equipment, Inc.
The PTAB granted settlement motions, terminating the IPRs against Harbor Freight Tools USA Inc. and MWE Investments, LLC while leaving Generac Power Systems as the remaining petitioner. Settlement agreements are to be kept confidential under 35 U.S.C. § 317(b).
Generac Power Systems, Inc. et al. v.Champion Power Equipment, Inc.
The Director has initiated a sua sponte review of the Board’s institution decision in IPR2025‑00951, citing claim‑construction issues. The petition was filed by Generac and co‑petitioners against Champion Power’s generator patent.
Generac Power Systems, Inc. et al. v.Champion Power Equipment, Inc.
Generac, Harbor Freight, and MWE filed a joint request with the PTAB to keep their settlement agreement confidential, citing business‑confidential treatment under 35 U.S.C. §317(b). The request seeks to separate the agreement from the patent file and limit access to federal agencies or parties with good cause.
Aquestive Therapeutics, Inc. v.Iono Pharma, LLC
Aquestive Therapeutics seeks Director Review of the PTAB’s denial of institution for its IPR against Iono Pharma’s epinephrine prodrug patent. Iono Pharma argues the request fails statutory standards and should be denied.
Aquestive Therapeutics, Inc. v.Iono Pharma, LLC
Aquestive Therapeutics petitions the PTAB Director to overturn a discretionary denial of institution for an IPR on its epinephrine prodrug patent, arguing factual errors and improper reliance on settled‑expectation criteria.
Aquestive Therapeutics, Inc. v.Iono Pharma, LLC
The USPTO Director denied a request for review of the earlier decision denying institution of an IPR against Iono Pharma’s patent. The denial leaves the institution decision unchanged.
Oracle Corporation v.VirtaMove, Corp.
Oracle has filed an IPR petition seeking cancellation of nine claims of VirtaMove’s 2009 container‑technology patent, arguing the claims are obvious over existing container systems such as VServer, Solaris Zones, and Zap pods.
Oracle Corporation v.VirtaMove, Corp.
Oracle has filed a petition to invalidate all 18 claims of VirtaMove’s ’058 patent, asserting that the Callender reference renders the claims obvious. The petition also argues that any discretionary denial would be unwarranted.
Oracle Corporation v.VirtaMove, Corp.
Oracle has filed an IPR petition seeking cancellation of claims 1‑18 of VirtaMove’s ’058 patent, arguing obviousness over Elnozahy and Draves and a lack of written‑description support. The petition also challenges any discretionary denial, noting parallel filings by Google and Microsoft.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.